CD274 and neoplasm: To date, several potential predictive biomarkers for ICI treatment have been investigated, including PD-L1 expression by immunohistochemistry (IHC), the number of tumor-infiltrating lymphocytes, T-cell receptor clonality, tumor mutational burden, and tumor microenvironment (TME) features [2].